AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| AbbVie (NYSE: ABBV) | Delayed: 284.75 -0.05 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $284.80 | 52 Week High | $68.12 | |||
| Open | $284.57 | 52 Week Low | $50.71 | |||
| Day High | $285.36 | P/E | 61.77 | |||
| Day Low | $278.01 | EPS | $4.61 | |||
| Volume | 3,234,515 | |||||
